Quick Answer
Decoy Therapeutics Inc. reported Total Revenue of $0.00 for fiscal year 2022.
Decoy Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $0.00 -100.0% |
$1.84M -64.8% |
$5.23M +51.0% |
| Revenue (ASC 606) | — | — | — | $0.00 -100.0% |
$1.84M -64.8% |
$5.23M +51.0% |
| Net Income | -$12.52M -124.5% |
-$5.58M +55.5% |
-$12.54M +60.3% |
-$31.61M -147.6% |
-$12.77M -73.7% |
-$7.35M -6.0% |
| Diluted EPS | -$129.10 -85.6% |
-$69.54 -126.2% |
-$30.74 -106.6% |
-$14.88 -92.7% |
-$7.72 -1444.0% |
-$0.50 |
| Total Assets | $11.06M +265.8% |
$3.02M -54.1% |
$6.59M -55.0% |
$14.65M -64.1% |
$40.83M +63.8% |
$24.93M +79.4% |
| Cash and Equivalents | $10.71M +339.9% |
$2.43M -58.7% |
$5.90M -51.3% |
$12.11M -58.6% |
$29.21M +162.8% |
$11.12M +197.4% |
| Stockholders Equity | $5.89M +289.6% |
$1.51M -71.4% |
$5.29M -49.1% |
$10.38M -73.2% |
$38.72M +74.7% |
$22.16M +109.4% |
| R&D Expense | $368.2K -52.2% |
$770.0K -89.3% |
$7.17M -54.7% |
$15.84M +85.3% |
$8.55M +23.6% |
$6.91M +72.0% |
| Operating Income | -$12.61M -120.0% |
-$5.73M +55.5% |
-$12.89M +59.5% |
-$31.84M -148.5% |
-$12.81M -64.6% |
-$7.79M +5.8% |
| Shares Outstanding | — | 1.44M +192.7% |
492,304 -78.2% |
2.26M +24.7% |
1.81M -92.4% |
23.81M +427.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2023 | $0.00 | — | — |
| Revenue (ASC 606) | March 31, 2023 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$873.5K | +10.1% | +8.8% |
| Diluted EPS | September 30, 2025 | -$1.81 | +84.1% | -302.2% |
| Total Assets | September 30, 2025 | $6.10M | +58.0% | +337.8% |
| Cash and Equivalents | September 30, 2025 | $4.81M | +46.5% | +505.1% |
| Stockholders Equity | September 30, 2025 | $4.25M | +45.3% | +612.0% |
| R&D Expense | September 30, 2025 | $61.8K | -54.9% | -46.9% |
| Operating Income | September 30, 2025 | -$895.1K | +11.1% | +7.3% |
| Shares Outstanding | September 30, 2025 | 944,491 | -34.5% | -55.6% |
- Decoy Therapeutics Inc. reported Total Revenue of $0.00 for fiscal year 2022.
- Decoy Therapeutics Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Decoy Therapeutics Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2022.
- Decoy Therapeutics Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Decoy Therapeutics Inc. reported Net Income of -$12.52 million for fiscal year 2025.
- Decoy Therapeutics Inc. showed a decrease of -124.5% in Net Income compared to the prior fiscal year.
- Decoy Therapeutics Inc. reported Diluted EPS of $129.10 per share (loss) for fiscal year 2025.
- Decoy Therapeutics Inc. showed a decrease of -85.6% in Diluted EPS compared to the prior fiscal year.
- Decoy Therapeutics Inc. reported Total Assets of $11.06 million for fiscal year 2025.
- Decoy Therapeutics Inc. showed an increase of +265.8% in Total Assets compared to the prior fiscal year.
- Decoy Therapeutics Inc. reported Cash and Equivalents of $10.71 million for fiscal year 2025.
- Decoy Therapeutics Inc. showed an increase of +339.9% in Cash and Equivalents compared to the prior fiscal year.
- Decoy Therapeutics Inc. reported Stockholders Equity of $5.89 million for fiscal year 2025.
- Decoy Therapeutics Inc. showed an increase of +289.6% in Stockholders Equity compared to the prior fiscal year.
- Decoy Therapeutics Inc. reported R&D Expense of $368.2 thousand for fiscal year 2025.
- Decoy Therapeutics Inc. showed a decrease of -52.2% in R&D Expense compared to the prior fiscal year.
- Decoy Therapeutics Inc. reported Operating Income of -$12.61 million for fiscal year 2025.
- Decoy Therapeutics Inc. showed a decrease of -120.0% in Operating Income compared to the prior fiscal year.
- Decoy Therapeutics Inc. reported Shares Outstanding of 1.44 million shares for fiscal year 2024.
- Decoy Therapeutics Inc. showed an increase of +192.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: